Joshua Bauml's guest appearances

Joshua Bauml

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

PeerView Internal Medicine CME/CNE/CPE Video Podcast

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast

PeerView Clinical Pharmacology CME/CNE/CPE Video

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

Best of Oncology Podcast Series

2016 ASCO Annual Meeting

Alan P Venook

Ghassan Abou-Alfa

Kevin Song

Meletios Dimopolous

James Perry

Arjun Balar

Antonio Palumbo

Michele Cavo

Sara M Tolaney

Paul Goss

Julie Vose

Charles Rudin

Richard Schilsky

Richard Gomez

Nikhil Wagle

OwlTail

Andrew Robinson

Oncologists Dr. Andrew Robinson and Dr. Joshua Bauml, in conversation at the 2019 Eastern Canadian Oncology Opinion Series, discuss their experience with the changing landscapes in cancer care.

Oncologists Dr. Andrew Robinson and Dr. Joshua Bauml, in conversation at the 2019 Eastern Canadian Oncology Opinion Series, discuss their experience with the changing landscapes in cancer care.

Oncologists Dr. Andrew Robinson and Dr. Joshua Bauml discuss cancer care

Dr Bauml speaks with ecancertv at ASCO 2016 to discuss the first findings of KEYNOTE 055, a trial for PD-L1/2 blocking pembrolizumab for patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).Pembrolizumab showed promising anti-tumour activity in earlier KEYSTONE 012 results, which are confirmed in this setting with an overall recovery rate of 18% and a stable disease rate of 18%.Dr Bauml discusses the impact of these findings for those whom platinum and cetuximab therapy had failed, the wider aspects of checkpoint inhibitory therapy, and next steps for the trial.

Dr Bauml speaks with ecancertv at ASCO 2016 to discuss the first findings of KEYNOTE 055, a trial for PD-L1/2 blocking pembrolizumab for patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Pembrolizumab showed promising anti-tumour activity in earlier KEYSTONE 012 results, which are confirmed in this setting with an overall recovery rate of 18% and a stable disease rate of 18%. Dr Bauml discusses the impact of these findings for those whom platinum and cetuximab therapy had failed, the wider aspects of checkpoint inhibitory therapy, and next steps for the trial.

Preliminary results from KEYNOTE-055: pembrolizumab in HNSCC - Dr Joshua Bauml